Psoriasis (PsO) is a chronic, inflammatory skin disorder affecting about 1%-3% of the world’s population. There are many challenges in diagnosing and successfully managing individuals with PsO. For example, while there are similarities in PsO among ethnic groups, there are notable differences in presentation, quality of life, and treatment of PsO in people with skin of color.
The first episode of this four-episode CME Outfitters BriefCase learning series includes a video clinical encounter on differentiating PsO in people with skin of color, based on notable differences in disease presentation.
At the end of this CME/CE activity, participants should be able to improve diagnostic accuracy of psoriasis (PsO) in patients with skin of color, based on knowledge of notable difference in disease presentation.
The following learning objectives pertain only to those requesting CNE or CPE credit: Explain how to improve diagnostic accuracy of PsO in patients with skin of color, based on knowledge of notable differences in disease presentation.
Supported by educational grants from Celgene and Novartis Pharmaceuticals Corporation.
Dermatologists, primary care physicians, nurse practitioners, physician assistants, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gelfand reports that he receives grants from AbbVie Inc.; Boehringer Ingelheim; Celgene Corporation; Janssen Biologics, Inc.; Novartis Corporation; Ortho Dermatologics; and Pfizer Inc. He is a consultant for Boehringer Ingelheim; Bristol-Myers Squibb Company; Janssen Biologics, Inc.; NeuroDerm Data and Safety Monitoring Board (DSMB); Novartis Corporation; Pfizer Inc.; Sun Pharmaceutical Industries; and UCB Data and Safety Monitoring Board (DSMB). He receives other financial or material support as a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma; and as Deputy Editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology.
Dr. Helfand (peer reviewer) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Call us at 877.CME.PROS (877.263.7767).